Kallidinogenase normalizes retinal vasopermeability in streptozotocin-induced diabetic rats: Potential roles of vascular endothelial growth factor and nitric oxide

Q3 · MEDICINE

Article

Author: Takagi, Hitoshi ; Suzuma, Kiyoshi ; Lu, Chunmei ; Matsumoto, Yukiharu ; Kato, Noriaki ; Hou, Yunlong ; Nagano, Hiroshi ; Lu, Zhenhui

We studied the suppressant effect of kallidinogenase on retinal vascular permeability and vascular endothelial growth factor (VEGF) in diabetic rats. Diabetes was induced by intravenously injecting streptozotocin (60 mg/kg body weight) dissolved in citrate buffer. Kallidinogenase (7 microg/kg/day) was injected intravenously once daily for 21 days. The retinal vascular permeability was estimated from the amount of fluorescent dye leaking into the retina after administration of fluorescein isothiocyanate-conjugated dextran. VEGF in intraocular fluids was quantified by an enzyme-linked immunosorbent assay. The amounts of nitrite and nitrate in the retina were quantified by a fluorescence method using 2,3-diaminonaphthalene. Retinal vascular permeability in the diabetic control group was about 5.5 times higher than in the normal control group (P<0.001). Kallidinogenase suppressed the increased retinal vascular permeability. In the diabetic control group, the VEGF level was three times that of the normal control group (diabetic control group, 160+/-12 pg/ml; normal control group, 54+/-9 pg/ml; P<0.001). The VEGF concentration in the kallidinogenase-treated group was 120+/-12 pg/ml (P<0.05). In the diabetic control group, the amounts of nitrite and nitrate in the retina were lower by about 2.6-fold, compared with the normal control group (P<0.05). Kallidinogenase almost normalized the decreases in nitrite and nitrate in the retina. The current study showed beneficial effects of kallidinogenase on increased retinal vascular permeability and VEGF in diabetic rats, suggesting that kallidinogenase may be effective for simple retinopathy in patients with diabetes.

01 Apr 1985·Clinical Otolaryngology

Treatment of sudden deafness: carbon dioxide and oxygen inhalation and steroids

Article

Author: H. Edamatsu ; M. Hasegawa ; N. Kurita ; T. Oku ; I. Watanabe ; T. Nigauri

The results of treating 86 patients with sudden deafness are reviewed in this paper. They were treated with intravenous ATP-2Na, Vitamin B1, B6, B12 and C, stellate ganglion block, peroral steroids, cyclandelate and Kallidinogenase. Fifty-one of 86 patients were additionally treated with carbon dioxide and oxygen inhalation. The first 35 patients (no gas inhalation group) and the latter 51 patients (gas inhalation group) were compared with each other concerning hearing improvement, and recovery rate associated with age of the patients, untreated period and effect of steroids. There was no statistical difference between the two groups with regard to these parameters.

100 Deals associated with Kallidinogenase(Kyowa Pharmaceutical Industry)

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Chorioretinitis	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	11 Jul 1988
Menopausal syndrome	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	11 Jul 1988
Poor peripheral circulation	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	11 Jul 1988

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Kallidinogenase(Kyowa Pharmaceutical Industry)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation